Ten patients were randomised to receive oral sulfasalazine (group 1) and 12 patients randomised to no treatment (group 2); all were followed for 3 years
Sulfasalazine is one medication that can be helpful to some people with severe disease
Sulfasalazine for ankylosing spondylitis
TNFi Despite treatment with NSAIDs, ACR strongly recommends treatment with TNFi over no treatment with TNFi, and conditionally recommends TNFi over treatment with tofacitinib
These findings
Use of
Eighty-five patients with active ankylosing spondylitis (AS) were randomized to receive either sulfasalazine (less than or equal to 3 gm/day, mean 2
The main clinical feature of AS is chronic
The main clinical feature of AS is chronic inflammatory back pain, AND (‘disease-modifying anti-rheumatic drugs' OR ‘DMARDs' OR ‘sulfasalazine'))
J All these consequences lead to the pathogenesis of ankylosing spondylitis (AS)
5) or placebo for 26 weeks
OBJECTIVES To evaluate the benefits and harms of sulfasalazine for the treatment of ankylosing spondylitis (AS)
Short-term use of muscle relaxants and pain relievers Ankylosing Spondylitis
Aim: To evaluate efficacy of sulfasalazine for axial ankylosing spondylosis
We report the case of a young male patient with ankylosing spondylitis treated with sulphasalazine who developed bilateral sensorineural hearing loss with tinnitus
Week 2: 500 mg orally twice a day (morning and evening) Week 3: 500 mg orally in the morning and 1000 mg in the evening
Objective: Etanercept, a fully human tumor necrosis factor soluble receptor, is effective in treatment of ankylosing spondylitis (AS)
Prolonged joint pain, back stiffness, and eye inflammation are common
Sulfasalazine is also used 'off-label' - for conditions it is not approved for - for ankylosing spondylitis, Crohn's disease and psoriatic arthritis
Sulfasalazine works best for peripheral arthritis symptoms or if /r/ankylosingspondylitis is a place for patients of ankylosing spondylitis and other axial spondyloarthritis